Font Size

SCREEN

Profile

Direction

Menu Style

In Brief
  1. ISIRV Journal: IRV Journal impact factor is now 4.4
  2. OPTIONS XII 29 Sept-2 Oct 2024 Brisbane, Australia
OPTIONS for the Control of Influenza XII

Reinhard Glüek, Executive Vice President R&D, Vaccine Discovery


Country of Residence: Switzerland

Contact Information
Berna Biotech Ltd, A Crucell Company
Rehhagstrasse 79
Berne, Switzerland, 3018
Tel: 0041 (0) 31 980 65 00
Fax: 0041 (0) 31 980 6785
E-mail: reinhard.glueck@bernabiotech.com
Research Interest and Areas of Expertise
Vaccinology, Immunology, Pharmacology, Biotechnology, Virology, Microbiology, Parasiteology
Education and Certifications
MagPhilNat (Biology and Chemistry)
LicPhilNat (Microbiology)                                                                                                  
PhDPhilNat (Microbiology and Immunochemistry)                                                         
Teaching
University of Genova, Italy, Teaching Professor
University "La Sapienza", Rome, Italy
University of Catania, Italy, Visiting Professor
Publications
More than 200 peer reviewed publications and 9 patents
Selected Publications
  1. Glück R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine. 1999;17:1782-1787.
  2. Glück U, Gebbers J-O, Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without escherichia coli heat-labile toxin in adult volunteers. J Virol. 1999;73:7780-7786.
  3. Stefenson I., Nicholson KG, Glück R., Mischler R., Newman RW., Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet. 2003;362:1959-1966.
Advisory Panels
Integrated Biopharma(INB)
AMVAC                                                                                                                                   
Helmholtz Foundation
Nexatio
Leadership
Head Virology Berna Biotech, 1987-2000
Chief Scientific Officer Berna Biotech, Member of the Executive Committee, 2000-2006
Executive Vice President R & D, Vaccine Discovery, Berna Biotech a Crucell Company, 2006-present
President Etna Biotech, 2001-present
President Swiss Biotech Association (SBA), 2002-present
Chairman European Malaria Vaccine Development Association (EMVDA), 2006-present
Honours and Awards
No information available.
Memberships
Schweiz. Mikrobiologiche Gesellschaft
Dutsche Gesellschaft für Virologie
International Association of Biological Standardization
Commission of Experts of the WHO for Rabies, Measles, Mumps, Rubella, Hepatitis A
European Commission: Coordination of Vaccine Research
European Vaccine Manufacturer
European Commission: Biological Weapons
Member of Board of Global Alliance for Vaccines and Immunisation
Expert of European Pharmacopoeia
Board of World Vaccine Institution, Montreal
Member of Jury Swiss Life Sciences Price
CV or Biosketch